Filing Flows › Aligos Therapeutics (ALGS) › Q1 2026
Aligos Therapeutics (ALGS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Aligos Therapeutics (ALGS) reported revenue of $2.8M for the first quarter 2026 (Q1 2026), +810% from a year earlier and up 17-fold from the quarter before. Operating margin was -951.6%, net loss $23.0M (814.1% of revenue).
Aligos Therapeutics, Q1 2026: revenue $2.8M (+810% year over year), operating margin -951.6%, net loss $23.0M, operating cash flow −$23.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.8M | 17× | +810% |
| Operating profit | −$26.9M | — | — |
| Net earnings | −$23.0M | — | -153% |
| Operating cash flow | −$23.1M | — | — |
What changed
Revenue was $2.8M in Q1 2026, up 810% year over year and up 1575% from the previous quarter.
Operating costs exceeded revenue by $26.9M, an operating margin of -951.6%. Total costs grew 52% against revenue growth of 810%. The fastest-growing cost line was Research & development (+61%). The quarter ended with a net loss of $23.0M, wider than the previous quarter's $19.9M loss.
Operating cash flow was −$23.1M. Non-cash charges added back $346K of depreciation and $1.3M of share-based compensation. Working capital and other items used $1.7M.
Questions
What was Aligos Therapeutics' revenue in the first quarter 2026?
Aligos Therapeutics (ALGS) reported revenue of $2.8M for the first quarter 2026 (Q1 2026), +810% from a year earlier and up 17-fold from the quarter before.
Was Aligos Therapeutics profitable in the first quarter 2026?
Operating loss was $26.9M (-951.6% of revenue) and net loss $23.0M.